Literature DB >> 23749272

Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease.

Grace Gathungu1, Mi-Ok Kim, John P Ferguson, Yashoda Sharma, Wei Zhang, Sok Meng E Ng, Erin Bonkowski, Kaida Ning, Lisa A Simms, Anthony R Croft, Joanne M Stempak, Nicole Walker, Ning Huang, Yang Xiao, Mark S Silverberg, Bruce Trapnell, Judy H Cho, Graham L Radford-Smith, Lee A Denson.   

Abstract

BACKGROUND: Neutralizing autoantibodies (Abs) against granulocyte-macrophage colony-stimulating factor (GM-CSF Ab) have been associated with stricturing ileal Crohn's disease (CD) in a largely pediatric patient cohort (total 394, adult CD 57). The aim of this study was to examine this association in 2 independent predominantly adult inflammatory bowel disease patient cohorts.
METHODS: Serum samples from 742 subjects from the NIDDK IBD Genetics Consortium and 736 subjects from Australia were analyzed for GM-CSF Ab and genetic markers. We conducted multiple regression analysis with backward elimination to assess the contribution of GM-CSF Ab levels and established CD risk alleles and smoking on ileal disease location in the 477 combined CD subjects from both cohorts. We also determined associations of GM-CSF Ab levels with complications requiring surgical intervention in combined CD subjects in both cohorts.
RESULTS: Serum samples from patients with CD expressed significantly higher concentrations of GM-CSF Ab when compared with ulcerative colitis or controls in each cohort. Nonsmokers with ileal CD expressed significantly higher GM-CSF Ab concentrations in the Australian cohort (P = 0.002). Elevated GM-CSF Ab, ileal disease location, and disease duration more than 3 years were independently associated with stricturing/penetrating behavior and intestinal resection for CD.
CONCLUSIONS: The expression of high GM-CSF Ab is a risk marker for aggressive CD behavior and complications including surgery. Modifying factors include environmental exposure to smoking and genetic risk markers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23749272      PMCID: PMC3707315          DOI: 10.1097/MIB.0b013e318281f506

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  44 in total

Review 1.  MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis.

Authors:  Christian Jurinke; Paul Oeth; Dirk van den Boom
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

2.  Effects of current and former cigarette smoking on the clinical course of Crohn's disease.

Authors:  J Cosnes; F Carbonnel; F Carrat; L Beaugerie; S Cattan; J Gendre
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

3.  BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF.

Authors:  O D Schoch; U Schanz; M Koller; K Nakata; J F Seymour; E W Russi; A Boehler
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

4.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

5.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

6.  Tobacco consumption and disease duration are associated with fistulizing and stricturing behaviors in the first 8 years of Crohn's disease.

Authors:  Michael F Picco; Theodore M Bayless
Journal:  Am J Gastroenterol       Date:  2003-02       Impact factor: 10.864

7.  High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis.

Authors:  Kanji Uchida; Koh Nakata; Bruce C Trapnell; Takahiro Terakawa; Emi Hamano; Ayako Mikami; Ikumi Matsushita; John F Seymour; Masayoshi Oh-Eda; Ikuo Ishige; Yoshinobu Eishi; Takayuki Kitamura; Yoshitsugu Yamada; Kazuo Hanaoka; Naoto Keicho
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

8.  Negative association between smoking and anti-saccharomyces cerevisiae antibodies in Crohn's disease.

Authors:  C Van Kemseke; J Belaïche; C Steeman; E Louis
Journal:  Acta Gastroenterol Belg       Date:  2003 Jan-Mar       Impact factor: 1.316

9.  Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype.

Authors:  E Louis; V Michel; J P Hugot; C Reenaers; F Fontaine; M Delforge; F El Yafi; J F Colombel; J Belaiche
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

10.  The influence of conditioned medium from mouse intestinal epithelial cells on the proliferative activity of crypt cells: role of granulocyte-macrophage colony-stimulating factor.

Authors:  Sergey V Sennikov; Vladimir V Temchura; Vladimir A Kozlov; Valeriy A Trufakin
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

View more
  37 in total

1.  NOD2 modulates immune tolerance via the GM-CSF-dependent generation of CD103+ dendritic cells.

Authors:  David Prescott; Charles Maisonneuve; Jitender Yadav; Stephen J Rubino; Stephen E Girardin; Dana J Philpott
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

2.  Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease.

Authors:  Cortney R Ballengee; Ryan W Stidham; Chunyan Liu; Mi-Ok Kim; Jarod Prince; Kajari Mondal; Robert Baldassano; Marla Dubinsky; James Markowitz; Neal Leleiko; Jeffrey Hyams; Lee Denson; Subra Kugathasan
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-10       Impact factor: 11.382

Review 3.  Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.

Authors:  Weiwei Jiang; Xuhang Li
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

4.  Cytokine refacing effect reduces granulocyte macrophage colony-stimulating factor susceptibility to antibody neutralization.

Authors:  Pete Heinzelman; Sharon J Carlson; George N Cox
Journal:  Protein Eng Des Sel       Date:  2015-04-07       Impact factor: 1.650

5.  Genetic and Transcriptomic Variation Linked to Neutrophil Granulocyte-Macrophage Colony-Stimulating Factor Signaling in Pediatric Crohn's Disease.

Authors:  Lee A Denson; Ingrid Jurickova; Rebekah Karns; Kelly A Shaw; David J Cutler; David Okou; C Alexander Valencia; Anne Dodd; Kajari Mondal; Bruce J Aronow; Yael Haberman; Aaron Linn; Adam Price; Ramona Bezold; Kathleen Lake; Kimberly Jackson; Thomas D Walters; Anne Griffiths; Robert N Baldassano; Joshua D Noe; Jeffrey S Hyams; Wallace V Crandall; Barbara S Kirschner; Melvin B Heyman; Scott Snapper; Stephen L Guthery; Marla C Dubinsky; Neal S Leleiko; Anthony R Otley; Ramnik J Xavier; Christine Stevens; Mark J Daly; Michael E Zwick; Subra Kugathasan
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

6.  Familial Association of Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Inflammatory Bowel Disease.

Authors:  Sandra S Wright; Anna Trauernicht; Erin Bonkowski; Courtney A McCall; Elizabeth A Maier; Ramona Bezold; Kathleen Lake; Claudia Chalk; Bruce C Trapnell; Mi-Ok Kim; Subra Kugathasan; Lee A Denson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-05       Impact factor: 2.839

7.  The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities.

Authors:  Urmi Dhagat; Timothy R Hercus; Sophie E Broughton; Tracy L Nero; Karen S Cheung Tung Shing; Emma F Barry; Christy A Thomson; Steve Bryson; Emil F Pai; Barbara J McClure; John W Schrader; Angel F Lopez; Michael W Parker
Journal:  MAbs       Date:  2018-09-12       Impact factor: 5.857

8.  GM-CSF and the role of myeloid regulatory cells in the pathogenesis and treatment of Crohn's disease.

Authors:  Jan Däbritz
Journal:  Mol Cell Pediatr       Date:  2015-12-01

9.  mTOR Inhibition Attenuates Dextran Sulfate Sodium-Induced Colitis by Suppressing T Cell Proliferation and Balancing TH1/TH17/Treg Profile.

Authors:  Shurong Hu; Mengmeng Chen; Yilin Wang; Zhengting Wang; Yaofei Pei; Rong Fan; Xiqiang Liu; Lei Wang; Jie Zhou; Sichang Zheng; Tianyu Zhang; Yun Lin; Maochen Zhang; Ran Tao; Jie Zhong
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

10.  Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.

Authors:  Annelie Hellvard; Lutz Zeitlmann; Ulrich Heiser; Astrid Kehlen; André Niestroj; Hans-Ulrich Demuth; Joanna Koziel; Nicolas Delaleu; Piotr Mydel
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.